Sanofi (NASDAQ:SNY) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its position in shares of Sanofi (NASDAQ:SNY) by 408.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 160,339 shares of the company’s stock after buying an additional 128,811 shares during the period. The Manufacturers Life Insurance Company’s holdings in Sanofi were worth $9,244,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the period. Magnetar Financial LLC boosted its holdings in Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after acquiring an additional 2,306,286 shares during the period. Jennison Associates LLC grew its position in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the period. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of SNY opened at $48.17 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $122.25 billion, a P/E ratio of 24.58, a PEG ratio of 1.22 and a beta of 0.58. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The stock has a fifty day moving average price of $52.61 and a 200 day moving average price of $52.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period last year, the firm posted $2.55 EPS. Sanofi’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts forecast that Sanofi will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on SNY. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and an average target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.